PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIA...

por Al-Ali, Haifa Kathrin, Mesa, Ruben, Hamer-Maansson, J.E., Braunstein, Evan, Harrison, Claire
Publicado 2023

P1045: DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN PATIENTS WITH LOWER-RISK MYELOFIBROSIS: AN ANALYSIS FROM MOST

por Komrokji, Rami S., Grunwald, Michael, Braunstein, Evan, Hamer-Maansson, J.E., Kalafut, Tricia, Mascarenhas, John
Publicado 2023

P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS

por Grunwald, Michael, Ritchie, Ellen, Rumi, Elisa, Assad, Albert, Hamer-Maansson, J.E., Yu, Jingbo, Braunstein, Evan, Passamonti, Francesco
Publicado 2023

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES

por Harrison, C., Kiladjian, J.-J., Vannucchi, A. M., Mesa, R. A., Scherber, R. M., Hamer-Maansson, J., Verstovsek, S.
Publicado 2022

P1062: A REAL-WORLD EVALUATION OF THE ASSOCIATION BETWEEN ELEVATED BLOOD COUNTS AND THROMBOTIC EVENTS IN POLYCYTHEMIA VERA: AN ANALYSIS OF DATA FROM THE REVEAL STUDY

por Gerds, A. T., Mesa, R., Burke, J. M., Grunwald, M. R., Scherber, R., Yu, J., Hamer-Maansson, J., Oh, S. T.
Publicado 2022